Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23718677 | 0.88 | FAAH (0.52) | PSMB5CTSBCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26154325 | 0.85 | FAAH (0.52) | PSMB5FAAHPTPN1 | |
| SCHEMBL26154311 | 0.85 | FAAH (0.52) | PSMB5FAAHPTPN1 | |
| SCHEMBL25497019 | 0.84 | FAAH (0.60) | PSMB5CTSBCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24982484 | 0.83 | FAAH (0.50) | PSMB5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25148144 | 0.83 | FAAH (0.56) | PSMB5CTSBCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24577164 | 0.82 | FAAH (0.49) | PSMB5FAAHPTPN1 | |
| SCHEMBL26154352 | 0.82 | REN (0.45) | PSMB5CTSBOPRD1OPRM1REN | |
| SCHEMBL24183714 | 0.81 | FAAH (0.53) | PSMB5CTSBCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27109780 | 0.81 | CHRNB2 (0.52) | PSMB5CTSBCHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | PSMB5 2171/4885CTSB 2095/4885CHRNB2 2213/4885 |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | XPOT, ENGASE, ENTPD8 | PSMB5 2171/4885CTSB 2095/4885CHRNB2 2213/4885 |
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | PSMB5 2171/4885CTSB 2095/4885CHRNB2 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.